Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

NCT05315687 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT05315687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05315687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Withdrawn
Start date
August 17, 2022
Completion date
July 31, 2025
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, metastatic breast carcinoma, metastatic carcinoma in the liver, prognostic stage iv breast cancer ajcc v8